GEN Digital Launches Phase II Trial of Mitochondrial Therapy SUL‑238 to Target Parkinson’s Disease
GEN Digital’s Phase II SHEPHERD trial of mitochondrial‑targeting therapy SUL‑238 for Parkinson’s disease shows how biomarker‑driven, early‑intervention research could shift the disease‑modifying paradigm.
4 minutes to read









